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Abstract The subcutaneous Matrigel plug assay in mice
is a method of choice for the in vivo evaluation of pro- and
anti-angiogenic molecules. However, quantification of the
angiogenic response in the plug remains a problematic task.
Here we report a simple, rapid, unbiased and reverse
transcription-quantitative PCR (RT-qPCR) method to
investigate the angiogenic process occurring in the Matri-
gel plug in response to fibroblast growth factor-2 (FGF2).
To this purpose, a fixed amount of human cells were added
to harvested plugs at the end of the in vivo experimentation
as an external cell tracer. Then, mRNA levels of the pan-
endothelial cell markers murine CD31 and vascular
endothelial-cadherin were measured by species-specific
RT-qPCR analysis of the total RNA and data were nor-
malized for human GAPDH or b-actin mRNA levels. RT-
qPCR was used also to measure the levels of expression in
the plug of various angiogenesis/inflammation-related
genes. The procedure allows the simultaneous, quantitative
evaluation of the newly-formed endothelium and of non-
endothelial/inflammatory components of the cellular infil-
trate in the Matrigel implant, as well as the expression of
genes involved in the modulation of the angiogenesis
process. Also, the method consents the quantitative
assessment of the effect of local or systemic administration
of anti-angiogenic compounds on the neovascular response
triggered by FGF2.
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Introduction
Angiogenesis plays a key role in various physiological and
pathological conditions, including embryonic development,
wound repair, inflammation, and tumor growth [1]. The
uncontrolled release of angiogenic growth factors, includ-
ing fibroblast growth factor-2 (FGF2), vascular endothelial
growth factor-A (VEGF-A) and other members of the FGF
and VEGF families [2, 3], is responsible for the endothelial
cell proliferation that takes place during tumor neovascu-
larization and angiogenesis-dependent diseases [4]. The
identification of anti-angiogenic drugs and of angiogenesis
related targets may have significant implications for the
development of anti-neoplastic therapies, as shown by the
positive outcomes in the treatment of angiogenesis-
dependent neoplastic and non-neoplastic diseases with
anti-VEGF drugs [5].
Various in vivo models have been developed in different
animal species, ranging from zebrafish to rodents, to
investigate the angiogenesis process and for the screening of
pro- and anti-angiogenic compounds, each with its own
unique characteristics, advantages and disadvantages [6–
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10]. Among them, the Matrigel plug assay has become a
method of choice [10, 11]. Matrigel, a laminin-rich recon-
stituted matrix is an extract of the Engelbreth-Holm-Swarm
tumor composed of basement membrane components [12].
In the Matrigel plug assay, an angiogenic stimulus (usually
represented by recombinant growth factors or tumor cells) is
introduced into cold liquid Matrigel which, following sub-
cutaneous (s.c.) injection in mice, gelifies and allows the
recruitment of a new microvascular network [11].
Assessment of the angiogenic response in the Matrigel
plug assay is routinely achieved by determination of the
hemoglobin content of the plug or by histological/immu-
nohistochemical analysis of vascular density in selected
regions of plug slides [11]. However, both procedures
present significant drawbacks that may affect the accurate
quantification of the new microvascular network [7, 10].
Indeed, evaluation of the hemoglobin content is affected by
the patency and size of the infiltrating vessels and by the
presence of stagnant pools of blood, especially when heparin
is added to the gel with possible hemorrhagic consequences.
On the other hand, histological/immunohistochemical
assessment of vascular density is strongly affected by its
high intra-sample heterogeneity (see below) that may be
overcome only by averaging the data from numerous tissue
slides for each plug, thus resulting in a tedious, operator’s
subjective procedure [7].
Here we report a simple, rapid and unbiased method to
quantify the new microvascular network elicited by FGF2 in
the Matrigel plug assay by measuring the steady-state tran-
script levels of endothelial cell markers present in the plug
by reverse transcription-quantitative PCR (RT-qPCR). The
procedure also allows the simultaneous, quantitative evalua-
tion of non-endothelial components of the cellular infiltrate
and of the expression of genes involved in the modulation of
the angiogenesis process in the Matrigel plug. RT-qPCR
analysis was used also to assess the anti-angiogenic effect
exerted in vivo by the local or systemic administration of
FGF2 antagonists. This procedure will facilitate the quanti-
fication of in vivo angiogenesis experiments, essential for
testing novel angiogenic and anti-angiogenic agents.
Materials and methods
Reagents and cells
Human recombinant FGF2 was from Tecnogen (Piana di
Monteverna, Caserta, Italy). Matrigel (Cultrex BME
Growth Factor Reduced) was from Trevigen (Gaithersburg,
MD), SU5402 from Calbiochem (Darmstadt, Germany),
PD173074 from Sigma-Aldrich (St. Louis, MO), and FGF-
ligand trap (FGFR1-Fc) from Relia Tech GmbH (Wol-
fenbuttel, Germany). Human endometrial adenocarcinoma
HEC-1-B cells [13] were obtained from American Type
Culture Collection (Rockville, MD) and grown in MEM
supplemented with 1 % nonessential amino acids, 1 %
sodium pyruvate, and 10 % fetal bovine serum. Murine
lung microvascular endothelial 1G11 cells [14] were
obtained from A. Vecchi (Istituto Scientifico Humanitas,
Rozzano, Milan, Italy) and cultured in Dulbecco modified
Eagle medium (DMEM) containing 20 % inactivated fetal
bovine serum (FBS).
Matrigel plug angiogenesis assay
Liquid Matrigel (10–16 mg of protein/ml) was mixed at
4 C with FGF2 dissolved in PBS at a final concentration
equal to 1.0 lg/ml unless specified otherwise and injected
subcutaneously (0.5 ml/mouse) into the flank of 6–8 week-
old C57BL/6 mice (Charles River, Calco, Italy). Matrigel
with PBS alone was used as negative control. One week
after injection, mice were sacrificed and plugs were har-
vested, weighted and processed for RT-qPCR analysis.
When specified, harvested plugs were divided in two parts,
one half underwent RT-qPCR analysis whereas the other
half was embedded in Tissue Tec OCT (Sigma-Aldrich),
snap-frozen by immersion in liquid nitrogen-cooled iso-
pentane and analysed by immunofluorescence microscopy.
RNA extraction and RT-qPCR analysis of Matrigel
plugs
Total RNA was extracted from Matrigel plugs using TRI-
zol reagent according to manufacturer’s instructions
(Invitrogen, Carlsbad, CA). Before RNA extraction, plugs
were added with an appropriate volume of TRIzol solution
containing human HEC-1-B cells to a final concentration of
1 9 104 cells per mg of Matrigel. Purified total RNA were
dissolved in RNase free water (1 ll per mg of Matrigel).
Contaminating DNA was digested using DNase as in the
DNase 1 Amplification Grade kit (Sigma-Aldrich). Four ll
of total RNA were retro-transcribed with M-MLV reverse
transcriptase (Invitrogen, Carlsbad, CA) using random
hexaprimers in a final 20 ll volume. Quantitative PCR was
performed with a Biorad iCycler iQTM Real-Time PCR
Detection System using a iQTM SYBR Green Supermix
(Biorad) according to manufacturer’s instructions. Each
PCR reaction was performed in triplicate on one plate and
fluorescence data were recorded using iCycler software
(BioRad). Relative expression ratios were calculated by use
of Pfaffl equation and Relative Expression Software Tool
(http://www.gene-quantification.info). The mRNA expres-
sion levels of target genes were normalized to the levels of
mGAPDH and/or hGAPDH or hb-actin housekeeping
genes, as specified in the text. In each experiment, an
arbitrary value equal to 1.0 was assigned to the levels of
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expression of the gene(s) measured in one PBS plug that
was used as reference sample.
In one in vitro preliminary experiment, increasing
amounts of murine endothelial 1G11 cells were resus-
pended in 800 ll of liquid Matrigel, then cell suspensions
were divided in two aliquots and incubated at 37 C to
allow gelification. Then, each aliquot was added with
500 ll of TRIzol reagent in the absence or in the presence
of human HEC-1-B cells (1 9 104 cells per mg of Matri-
gel). Finally, total RNA was extracted from Matrigel
samples for RT-qPCR analysis. The list of oligonucleotide
primer sequences utilized in the present work (final con-
centration 400 nM) are shown in Online Resource 1, Table
S1. Control experiments confirmed the lack of murine/
human species cross-reactivity of these primers.
Immunoistochemical analysis of the Matrigel plugs
Seven lm-frozen sections of Matrigel plugs were fixed in ice-
cold acetone and blocked with 10 % goat serum in Tris-
buffered saline. To evaluate microvessel density, sections
were stained with rat IgG2a anti-mCD31 monoclonal anti-
body (1/200 dilution, BD Pharmingen, San Diego, CA) fol-
lowed by incubation with biotinylated goat anti-rat IgG
antibody (1/200 dilution Santa Cruz, CA). Sections were then
exposed to avidin–biotin-peroxidase complex Vectastain
ABC Kit (Vector, Burlingame, CA) and peroxidase color
reaction was developed with 3-amino 9-ethyl carbazole AEC
Peroxidase substrate kit (Vector). Finally, sections were
lightly counterstained with Mayer’s hematoxylin. Images
were acquired using a Zeiss fluorescence microscope (Zeiss
Inc., North America) equipped with an Olympus N547 digital
camera (Olympus, Hamburg, Germany) at 2009 magnifica-
tion. The regions containing the most intense mCD31? areas
of neovascularization (‘‘hotspots’’) were chosen for quanti-
fication (see Online Resource 1, Fig. S1). Five hotspots per
Matrigel section and two sections per Matrigel plug were
analysed at 2009 magnification. The ImagePro Plus analysis
system was used to measure mCD31? areas in each hotspot
that were expressed as lm2 per microscopic field.
Statistical analysis
Statistical analysis was performed with 2-tailed Student’s
t-test. Differences were considered statistically significant
at P \ 0.05.
Results and discussion
FGF2 induces a robust angiogenic response in the murine
s.c. Matrigel plug assay characterized by the presence of
numerous CD31? blood vessels and an abundant
inflammatory cell infiltrate [15]. In a first set of experi-
ments, in order to quantify the newly formed endothelium
recruited by FGF2 in Matrigel plugs, we attempted to
measure the relative mRNA levels of the murine pan-
endothelial marker mCD31 in FGF2-embedded and control
implants by RT-qPCR. However, the limited cellularity in
control plugs resulted in a very low yield of total RNA
when compared to FGF2 plugs, making the comparison
between the two sets of samples unreliable. Moreover, no
significant difference was observed between the two
experimental groups when the levels of mCD31 mRNA in
each plug were normalized for the levels of expression of
the murine housekeeping gene mGAPDH (data not shown).
Indeed, as stated above, FGF2 driven neovessel formation
in the Matrigel plug is paralleled by the recruitment of
numerous inflammatory cells. Thus, endothelial cells rep-
resent a roughly constant fraction of the total cells infil-
trating the plug both in the absence and in the presence of
FGF2 [15]. Thus, no significant differences are detectable
between FGF2 and control plugs when the transcript levels
of an endothelial marker are normalized for a pan-cellular
murine housekeeping gene.
To overcome these technical drawbacks, we decided to
add an independent external cellular tracer to each har-
vested plug at the end of experimentation to improve RNA
recovery and to provide an internal control for RNA yield
and for the efficiency of RT-qPCR amplification among the
different samples. The cellular tracer is represented by a
fixed number of human cells added to the plug per mg of
pellet. Then, the levels of mCD31 mRNA and of human
GAPDH (hGAPDH) are measured in the final total cellular
extract using species-specific oligonucleotide primers and
data are expressed as mCD31/hGAPDH mRNA ratio. This
approach overcomes the problem of the poor cellularity of
control versus FGF2-plugs and allows the quantification of
murine endothelial markers independently of other com-
ponents of the host cellular infiltrate.
A preliminary experiment was carried out in vitro to
assess whether the addition of human cells to the plugs
could interfere with the quantification of the mCD31
mRNA and to estimate the linearity of the method. To this
purpose, murine CD31? endothelial 1G11 cells [14] were
added in vitro to the gel suspension in absence or in the
presence of a fixed amount of human cells (1 9 104 cells
per mg of Matrigel). In the present work, human endo-
metrial adenocarcinoma HEC-1-B cells [13] were used for
normalization even though similar results can be obtained
with any other human cell line available. After gelling,
total RNA was extracted from each sample and the levels
of mCD31, mGAPDH and hGAPDH transcripts were
assessed by RT-qPCR using species-specific oligonucleo-
tide primers (Online Resource 1, Table S1). Control
experiments showed that addition of the human cells to the
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plugs does not interfere with murine mRNA quantification
(data not shown). When a standard curve of 1G11 cells
(ranging between 2 9 105 and 5 9 106 cells) was prepared
in the presence of human cells, normalization of the data
demonstrated that the mCD31/mGAPDH mRNA ratio was
constant for all the samples tested whereas the mCD31/
hGAPDH mRNA ratio and the mGAPDH/hGAPDH mRNA
ratio were linearly related to the number of 1G11 cells
present in the sample (Fig. 1).
On this basis, control and FGF2-Matrigel plugs were
injected subcutaneously into the flank of 6–8 week-old
C57BL/6 mice. After 1 week, plugs were harvested,
weighed and homogenized in a TRIzol solution. Then, each
sample was divided in two aliquots and one aliquot was
added with human cells resuspended in TRIzol to a final
concentration of 1 9 104 human cells per mg of plug. After
extraction, total RNA was dissolved in water (1 ll of H2O
per mg of Matrigel) and a fixed volume was retro-tran-
scribed and used for qPCR analysis of mCD31, mGAPDH
and hGAPDH transcript levels in each sample. An arbitrary
value equal to 1.0 was assigned to the levels of expression
of the different genes measured in one PBS plug that was
used as reference sample. Again, addition of human cells
did not affect the quantification of mCD31 and mGAPDH
transcripts in the different samples both in control and
FGF2-plugs (data not shown). Also, only a limited 2 fold
increase of the mCD31/mGAPDH mRNA ratio was
observed in FGF2 plugs when compared to controls,
further confirming that data normalization for mGAPDH
expression levels masks the anticipated differences in plug
vascularity between the two experimental groups (Fig. 2a).
At variance, when the expression of mCD31 mRNA was
normalized for the hGAPDH transcript levels, a dramatic
increase of the mCD31/hGAPDH mRNA ratio was
observed in FGF2 versus control plugs (Fig. 2a). Accord-
ingly, in a second set of experiments we observed a 20–22
fold increase of mCD31 mRNA expression in FGF2
(n = 6) versus control (n = 4) plugs both when data were
normalized for hGAPDH mRNA levels or when normal-
ized for a different human housekeeping gene like human
b-actin; again, no significant difference between the two
experimental groups was observed when data were nor-
malized for murine b-actin expression (data not shown).
To further validate this experimental procedure, animals
were injected with Matrigel containing increasing amounts
of FGF2 ranging between 0.1 and 1.0 lg/ml. After 1 week,
plugs were harvested and processed for RT-qPCR analysis
after addition of human cells as external tracer as described
above. As shown in Fig. 2b, the results demonstrate a dose-
dependent increase of the mCD31/hGAPDH mRNA ratio,
thus confirming the quantitative capability of this in vivo
assay.
Even though CD31 is commonly used as an endothelial
cell marker, its expression is not restricted to endothelium,
being expressed to different degrees also on leukocyte sub-
types and platelets [16]. Moreover, cytokine combinations
may affect CD31 expression in endothelial cells (see [16]
and references therein). On this basis, we evaluated the
transcription levels of the murine endothelial marker vas-
cular endothelial-cadherin (mVE-cad) in the same plugs
used for the dose–response experiment described above
and originally analyzed for mCD31 expression. As shown
in Fig. 2b, the results demonstrate that similar dose-
dependent responses are obtained with FGF2 when quan-
tification of the recruited endothelium is expressed as mVE-
cad/hGAPDH or mCD31/hGAPDH mRNA ratio. Thus, the
simultaneous, quantitative assessment of various endothe-
lial markers in the same sample represents a further
advantage of this procedure and may provide an useful
control for those experimental conditions in which the
modulation of the expression of an endothelial marker may
occur.
The Matrigel plug assay is frequently used for the study
of anti-angiogenic compounds [10, 11]. On this basis, we
assessed the anti-angiogenic effect exerted in vivo by the
local or systemic administration of various FGF2 antago-
nists. Addition to FGF2 plugs of a FGF-ligand trap (a
fusion of mouse immunoglobulin Fc with a soluble FGFR1
construct [17]) or of the tyrosine kinase FGFR inhibitor
SU5402 [18] causes a significant decrease of newly-formed
endothelium as assessed by the reduction of mCD31/
Fig. 1 Quantification of endothelial cell-derived mCD31 mRNA
levels in Matrigel. Increasing concentrations of murine endothelial
1G11 cells (ranging between 1 9 105 and 5 9 106 cells) were added
in vitro to liquid Matrigel in the presence of human HEC-1-B cells
(1 9 104 cells per mg of Matrigel). Then, RT-qPCR analysis was
performed on the total RNA extracted from gelled Matrigel samples.
RT-qPCR data are expressed as mCD31/hGAPDH (filled circle),
mGAPDH/hGAPDH (open circle) and mCD31/mGAPDH (filled
triangle) mRNA ratio. Each point is the mean of 3 determinations.
Sample variability was \5 % of the mean values
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hGAPDH and mVE-cad/hGAPDH mRNA ratios (Fig. 3,
open bars). A similar inhibitory effect was exerted by the
systemic administration of the tyrosine kinase FGFR
inhibitor PD173074 [19]. Of note, very similar results were
obtained when mCD31 and mVE-cad expression data were
normalized for the human housekeeping gene hb-actin
(Fig. 3, black bars). These data demonstrate that RT-qPCR
analysis can be used to assess the effect of anti-angiogenic
compounds in the Matrigel plug assay.
Analysis of the vascularization of tumor biopsies is
usually performed by immunohistochemical staining of
tissue slides for a given endothelial antigen (e.g. CD31 or
Factor VIII-related antigen) followed by identification of
vascular ‘‘hotspots’’ and their quantification by computer-
ized image analysis [20]. Immunohistochemical assess-
ment of vascularity can be applied also for the analysis of
Matrigel plugs [10, 11]. On this basis, we compared the
results obtained when Matrigel plug vascularization was
quantified by RT-qPCR as described above or by mCD31
immunostaining. To this purpose, 12 mice were inoculated
s.c. with FGF2 plugs and 4 animals with control PBS plugs.
After 1 week, harvested plugs were divided in two parts:
one half was processed for RT-qPCR analysis whereas the
other half of the plug was included in OCT for mCD31
immunostaining and computerized image analysis of the
mCD31? hotspots. Various counting procedures have been
used for the immunohistochemical assessment of vascu-
larity in tumors, including differences in the number of
tissue blocks and of hotspots analyzed per sample (see Ref.
[21] for a thoughtful discussion of this point). Because of
the high heterogeneity of vascularization in different areas
of the same Matrigel plug (see below), the value of
mCD31? vascular density for each PBS or FGF2 plug was
calculated as the mean of the values measured in two tissue
sections on a total of 10 hotspots per plug.
As shown in Fig. 4a, immunohistochemical analysis
demonstrates that the observed increase of the mCD31/
hGAPDH mRNA ratio in FGF2 versus control plugs is
paralleled by a significant increase of mCD31? vessel
density within the implant. As frequently observed in
animal experimentation, a remarkable inter-sample vari-
ability occurs in PBS and FGF2 experimental groups
(Fig. 4b and Online Resource 1, Table S2). Indeed, the
mean mCD31? microvascular density ranged between
0.47 9 103 and 2.83 9 103 lm2/field and between
3.03 9 103 and 12.05 9 103 lm2/field for PBS and FGF2
implants, respectively. A similar variability was observed
when data were calculated as median values (Online
Resource 1, Table S2). Accordingly, the range of values
measured for the mCD31/hGAPDH mRNA ratio in the
different plugs was equal to 0.5–11.8 and 70.7–188.4 in
PBS and FGF2 groups, respectively (Fig. 4b). Next,
mCD31 expression levels and mCD31? vascular density
measured in the same Matrigel implants were compared by
linear regression analysis (Fig. 4b). Even though statisti-
cally significant (P = 0.013), the correlation between the
Fig. 2 Quantification of neovessel formation in Matrigel plugs by
RT-qPCR analysis. a Matrigel plugs containing PBS (open bars) or
0.3 lg/ml of FGF2 (black bars) were implanted s.c. in mice. After
1 week, plugs were harvested, weighted, homogenized in a TRIzol
solution, added with 1 9 104 human cells per mg of plug and
assessed for mCD31, mGAPDH and hGAPDH expression levels by
RT-qPCR. Data are the mean ± SEM of 7 plugs and are expressed
both as mCD31/mGAPDH and mCD31/hGAPDH mRNA ratios.
*P \ 0.05. b Matrigel pellets containing increasing concentrations of
FGF2 were implanted s.c. in mice. After 1 week, plugs were
processed as described in panel (a) and assessed for mCD31, mVE-
cad and hGAPDH expression levels by RT-qPCR. Data are the
mean ± SEM of 6 plugs per experimental point and are expressed as
mCD31/hGAPDH (open bars) and mVE-cad/hGAPDH (black bars)
mRNA ratios
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two assays was characterized by an elevated dispersion of
the data around the fitted line (R2 = 0.36). This is likely
due to the very high intra-sample variability of mCD31?
hotspot quantification analysis with plugs showing highly
vascularized zones together with poorly vascularized areas
(Online Resource 1, Fig. S1). Indeed, the value of a single
mCD31? hotspot ranged between 0.00 and 4.93 9 103
lm2/field for PBS implants and between 1.38 9 103 and
24.66 9 103 lm2/field for FGF2 implants (Online
Resource 1, Table S2). Possibly, this variability may be
overcome by averaging data from a much higher number of
tissue slides for each plug, resulting however in a tedious,
time-consuming and in any case operator’s subjective
procedure. At variance, RT-qPCR analysis allowed the
rapid, unbiased quantification of the levels of endothelial
cell transcripts present in the whole sample, thus mini-
mizing the intra-sample variability.
As stated above, the angiogenic response triggered by
FGF2 in the Matrigel plug assay is paralleled by an abundant
CD45? cellular infiltrate with numerous CD11b? mono-
cytes [15, 22] and NG2? pericytes [23], whereas only
scattered Gr-1? neutrophils, CD8? or CD4? T-lymphocytes
and no CD19? B-lymphocytes and NK1.1? natural killer
cells are detectable in FGF2 plugs [15, 22]. RT-qPCR
analysis confirmed that the significant increase of total
cellular infiltrate in FGF2 plugs (indicated by the increase of
the housekeeping mGAPDH/hGAPDH mRNA ratio) was
paralleled by a significant increase of the mCD45/hGAPDH,
mCD11b/hGAPDH and mNG2/hGAPDH mRNA values
(Fig. 5). At variance, in keeping with the immunohisto-
chemical data [15, 22], mGr-1, mCD8, mCD4, mCD19, and
mCD161 were expressed at very low levels in the plugs and
their transcripts were detected by RT-qPCR analysis only
after a very high number of amplification cycles, making the
data nonquantitative and unreliable (data not shown).
The induction of a pro-angiogenic/inflammatory infil-
trate by FGF2 goes along with the capacity of this growth
factor to up-regulate the expression of various pro-angio-
genic/pro-inflammatory genes as assessed on endothelial
cells in vitro [15, 22]. On this basis, to get a further insight
on the microenvironmental response elicited in vivo by
FGF2, we measured the levels of expression of the FGF2-
inducible pro-angiogenic/pro-inflammatory genes mVEGF-
A, cyclooxygenase-2 (mCox-2), chemokine (C–C motif)
ligand 2/MCP-1 (mCcl2) and chemokine (C–C motif)
ligand 7/MCP-3 (mCcl7) [15, 22] in PBS and FGF2 plugs.
As shown in Fig. 6a, the values of murine gene/hGAPDH
mRNA ratios are significantly increased in FGF2 versus
PBS implants for all the genes investigated, thus indicating
an absolute increase of their steady-state mRNA levels in
Fig. 3 Effect of local and systemic administration of FGF antago-
nists on FGF2-induced angiogenesis. Matrigel plugs containing
250 ng/plug of FGF2 were added with vehicle, 5 lg/plug of FGF-
ligand trap, or 12 lg/plug of SU5402 and implanted s.c. in mice. In
the same experiment, one group of animals implanted with FGF2
plugs was treated i.p. three times per week with 20 mg/kg of
PD173074 dissolved in DMSO. After 1 week, plugs were harvested,
weighted, homogenized in a TRIzol solution, added with 1 9 104
human cells per mg of plug, assessed for mCD31 (a) and mVE-cad
(b) expression levels by RT-qPCR and data were normalized for
hGAPDH (open bars) and hb-actin (black bars) expression. Data are
the mean ± SEM of 6 plugs per group. All treatments resulted in a
significant inhibition of FGF2 activity: *P \ 0.05 or better
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FGF2 plugs. At variance, when the data were calculated as
murine gene/mGAPDH mRNA ratios, only mCcl2 expres-
sion appeared to be significantly upregulated (Fig. 6b).
Together, the data strongly suggest that the observed
increase of mVEGF-A, mCox-2 and mCcl7 transcript levels
may represent the consequence of the increase of the total
cellular infiltrate in FGF2 plugs whereas the increase of
mCcl2 transcripts is due, at least in part, to a FGF2-med-
iated upregulation of gene expression in infiltrating cells
[15, 22]. Even though in situ hybridization analysis will be
required to fully elucidate this point, our findings demon-
strate that the RT-qPCR approach may represent an useful
tool to investigate the molecular events that go along with
the angiogenic process in Matrigel plugs.
The method herewith described is rapid, reproducible and
shows several advantages when compared to other experi-
mental procedures commonly used to quantify the angio-
genic response in the Matrigel plug assay, including
evaluation of the haemoglobin content of the plug or
immunohistochemical analysis of the newly formed capil-
lary network. Overall, the results validate the use of RT-
qPCR analysis for the simultaneous, quantitative evaluation
of newly-formed endothelium, non-endothelial components
of the cell infiltrate, and expression of genes involved in the
modulation of the angiogenesis process in the Matrigel plug.
Moreover, the same procedure was used to assess the effect
Fig. 4 Quantification of neovessel formation in Matrigel plugs: RT-
qPCR versus immunohistochemical analysis. a Matrigel plugs
containing PBS (n = 4) or 1.0 lg/ml of FGF2 (n = 12) were
implanted s.c. in mice. After 1 week, plugs were harvested and
divided in two aliquots. One aliquot was processed for determination
of the mCD31/hGAPDH mRNA ratio by RT-qPCR analysis (open
bars) whereas the second aliquot was processed for mCD31
immunostaining and evaluation of the CD31? hotspot areas by
computerized image analysis (black bars). Data are expressed as
mean ± SEM. *P \ 0.05. b For each plug, the individual value of
mCD31/hGAPDH mRNA ratio was plotted against the mean value of
its CD31? hotspot area. A statistically significant correlation
(P = 0.013) characterized by an elevated dispersion of the data
around the fitted linear regression line (R2 = 0.36) was observed
between the two parameters. open circle, PBS plugs; filled circle,
FGF2 plugs
Fig. 5 Evaluation of the cellular infiltrate in Matrigel plugs by RT-
qPCR analysis. Matrigel plugs containing PBS (open bars) or 1.0 lg/
ml of FGF2 (black bars) were implanted s.c. in mice. After 1 week,
plugs were processed for the evaluation of mGAPDH, mCD45,
mCD11b and mNG2 transcription levels by RT-qPCR and data were
expressed as murine gene/hGAPDH mRNA ratios. Data were
normalized to those measured in one PBS plug used as baseline
reference sample in which an arbitrary value equal to 1.0 was
assigned to the levels of expression of each investigated gene. The
procedure allows the comparison of mRNA levels between control
and FGF2 plugs for each single gene but not among the different
genes. The data are the mean ± SEM of 5–6 plugs per experimental
point; *P \ 0.05
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of local or systemic administration of putative anti-angio-
genic compounds. A similar quantitative approach can be
applied after addition to the gel of a suspension of pro-
angiogenic cells (e.g. syngeneic tumor cell lines) or of their
conditioned media (data not shown), further supporting the
handiness of this RT-qPCR procedure. Clearly, types and
amount of recruited cells in the Matrigel plug may vary
depending on experimental conditions. The use of primers
for cell type-specific markers (including endothelial, stromal
and inflammatory cells) rather than of nonspecific murine
housekeeping gene(s) may allow an accurate analysis of the
neovascularization process and cell infiltrate occurring in
the Matrigel plug under the different experimental condi-
tions. This method will facilitate the analysis and quantifi-
cation of in vivo angiogenesis experiments, essential for
testing novel angiogenic and anti-angiogenic agents.
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